Summary

Ten years of adjuvant tamoxifen is superior to 5 years in reducing the rates of late recurrence and death in women with estrogen receptor (ER)-positive breast cancer. Breast cancer mortality is reduced by about one third over 15 years when women with ER-positive tumors are treated with 5 years of adjuvant tamoxifen. The effect of an additional 5 years of treatment on breast cancer recurrence and death was examined in the randomized Phase 3 Adjuvant Tamoxifen: To Offer More? study [aTTom; ISRCTN17222211; Gray RG et al. J Clin Oncol 2013 (suppl; abstr 5)]